TORONTO, ONTARIO--(Marketwired - Jan. 5, 2017) -
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX
VENTURE:HEM)(OTCQX:HMTXF) announces the resignation of Robert Bard as a director of the Company effective December 15, 2016. The
Company would like to thank Mr. Bard for his valuable contributions and wishes him well with his future endeavors.
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell
therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company
to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical limb ischemia
(CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial targets a
participant's diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of
new blood vessels.
Hemostemix currently enrolls participants in the phase 2 trial at four sites in South Africa and two sites in Canada. The
Company recently received FDA clearance to commence clinical trials in the United States.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more
information, visit hemostemix.com or email office@hemostemix.com.
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined under the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts
and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates,"
"projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should"
occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management
on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future events, or otherwise.